Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, USA.
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
J Clin Endocrinol Metab. 2022 May 17;107(6):e2449-e2458. doi: 10.1210/clinem/dgac086.
Parathyroid hormone (PTH) gene mutations represent a rare cause of familial isolated hypoparathyroidism (FIH). These defects can cause hypoparathyroidism with increased or decreased serum levels of PTH through 1) impaired PTH synthesis; 2) induction of parathyroid cell apoptosis; or 3) secretion of bioinactive PTH molecules. Eight pathogenic mutations of this gene have been described previously.
Through describing 2 novel mutations of the PTH gene, we aim to extend the molecular basis for FIH and further refine the proposed mechanisms by which PTH mutations cause hypoparathyroidism.
Proband case reports were compiled with extended family analysis. The probands in both kindreds presented before age 10 days with hypocalcemia and elevated phosphate levels. Proband A had low PTH levels, whereas these levels were elevated in Proband B. Proband B was initially diagnosed with pseudohypoparathyroidism. Methylation analysis was performed of CpG dinucleotides within 3 GNAS differentially methylated regions; whole-genome sequencing; and PTH infusion with analysis of nephrogenous 3',5'-cyclic adenosine 5'-monophosphate.
Proband A had a novel heterozygous sequence change in exon 2 of the PTH gene, c.46_47delinsAA (p.Ala16Lys), and proband B had a novel homozygous nucleotide transition in PTH exon 3 (c.128G > A; p.G43E) that led to replacement of glycine by glutamic acid at position 12 of PTH 1-84. PTH 1-34 infusion demonstrated that renal responsiveness to PTH was intact and not antagonized by circulating bioinactive PTH.
PTH gene mutations are uncommon causes of hypoparathyroidism, but can be misdiagnosed as disorders of gland development or receptor function if PTH levels are decreased or elevated, respectively. Genetic testing should be considered early in the diagnostic approach to these presentations.
甲状旁腺激素 (PTH) 基因突变是家族性孤立性甲状旁腺功能减退症 (FIH) 的罕见病因。这些缺陷可通过以下方式导致甲状旁腺激素水平升高或降低引起的甲状旁腺功能减退症:1)甲状旁腺激素合成受损;2)诱导甲状旁腺细胞凋亡;或 3)分泌无生物活性的 PTH 分子。先前已经描述了该基因的 8 种致病性突变。
通过描述 PTH 基因的 2 个新突变,我们旨在扩展 FIH 的分子基础,并进一步细化 PTH 突变导致甲状旁腺功能减退症的拟议机制。
编译先证者病例报告并进行家系分析。两个家系中的先证者均在 10 天前出现低钙血症和高磷血症。先证者 A 的 PTH 水平较低,而先证者 B 的 PTH 水平升高。先证者 B 最初被诊断为假性甲状旁腺功能减退症。对 CpG 二核苷酸进行了 3 个 GNAS 差异甲基化区域的甲基化分析;全基因组测序;以及 PTH 输注和肾源性 3',5'-环腺苷酸 5'-单磷酸分析。
先证者 A 在 PTH 基因的外显子 2 中存在一个新的杂合序列变化,c.46_47delinsAA (p.Ala16Lys),先证者 B 在 PTH 外显子 3 中存在一个新的纯合核苷酸转换(c.128G > A;p.G43E),导致 PTH 1-84 第 12 位的甘氨酸被谷氨酸取代。PTH 1-34 输注表明,PTH 对肾脏的反应性完整,且不受循环无生物活性 PTH 的拮抗。
PTH 基因突变是甲状旁腺功能减退症的罕见病因,但如果 PTH 水平降低或升高,可能会误诊为腺体发育或受体功能障碍。如果出现这些表现,应早期考虑进行基因检测。